EVALUATION OF THE IMMUNOGENICITY OF THE DABIGATRAN REVERSAL AGENT IDARUCIZUMAB: POOLED ANALYSIS OF PHASE I DATA

Authors :: Ippei Ikushima
Stephan Glund
Benjamin Lang
Steven Ramael
Akiko Harada
Joachim Stangier
Viktoria Moschetti
Joanne van Ryn
Stephen Norris
Paul A. Reilly
Wouter Haazen
Susumu Imazu
Source :: Journal of the American College of Cardiology. 67:2289
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: business.industry
Immunogenicity
030208 emergency & critical care medicine
Idarucizumab
030204 cardiovascular system & hematology
Pharmacology
Dabigatran
03 medical and health sciences
0302 clinical medicine
Pooled analysis
Medicine
Cardiology and Cardiovascular Medicine
business
medicine.drug

Tools